# Oric Pharmaceuticals, Inc.: financial statements, quarterly

ORIC · Nasdaq · CIK 1796280 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/oric.md) · [Financials](/companies/oric/financials.md) · [Filings](/companies/oric/filings.md) · [Insiders](/companies/oric/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/oric/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(28.7)](/filings/0000950170-24-125471.md) | [(31.4) d](/filings/0000950170-25-022273.md) | [(29.0)](/filings/0000950170-25-063564.md) | [(36.0)](/filings/0000950170-25-107359.md) | [(38.3)](/filings/0001193125-25-280234.md) | [(39.6) d](/filings/0001193125-26-064005.md) | [(32.7)](/filings/0001193125-26-204047.md) | [(39.1)](/filings/0001193125-26-330631.md) | [(36.7)](/filings/0001193125-25-280234.md) | [(34.6) d](/filings/0001193125-26-064005.md) | [(39.6)](/filings/0001193125-26-204047.md) | [(45.3)](/filings/0001193125-26-330631.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(25.5)](/filings/0000950170-24-125471.md) | [(28.3) d](/filings/0000950170-25-022273.md) | [(25.0)](/filings/0000950170-25-063564.md) | [(32.0)](/filings/0000950170-25-107359.md) | [(34.6)](/filings/0001193125-25-280234.md) | [(36.3) d](/filings/0001193125-26-064005.md) | [(30.0)](/filings/0001193125-26-204047.md) | [(36.4)](/filings/0001193125-26-330631.md) | [(32.6)](/filings/0001193125-25-280234.md) | [(30.5) d](/filings/0001193125-26-064005.md) | [(35.8)](/filings/0001193125-26-204047.md) | [(41.5)](/filings/0001193125-26-330631.md) |
| Diluted EPS | $ per share | [(0.44)](/filings/0000950170-24-125471.md) | not reported | [(0.37)](/filings/0000950170-25-063564.md) | [(0.45)](/filings/0000950170-25-107359.md) | [(0.49)](/filings/0001193125-25-280234.md) | not reported | [(0.42)](/filings/0001193125-26-204047.md) | [(0.47)](/filings/0001193125-26-330631.md) | [(0.33)](/filings/0001193125-25-280234.md) | not reported | [(0.34)](/filings/0001193125-26-204047.md) | [(0.38)](/filings/0001193125-26-330631.md) |
| Basic EPS | $ per share | [(0.44)](/filings/0000950170-24-125471.md) | not reported | [(0.37)](/filings/0000950170-25-063564.md) | [(0.45)](/filings/0000950170-25-107359.md) | [(0.49)](/filings/0001193125-25-280234.md) | not reported | [(0.42)](/filings/0001193125-26-204047.md) | [(0.47)](/filings/0001193125-26-330631.md) | [(0.33)](/filings/0001193125-25-280234.md) | not reported | [(0.34)](/filings/0001193125-26-204047.md) | [(0.38)](/filings/0001193125-26-330631.md) |

- Research and development: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [26.2](/filings/0000950170-24-125471.md) | [23.4](/filings/0000950170-25-022273.md) | [56.4](/filings/0000950170-25-063564.md) | [49.8](/filings/0000950170-25-107359.md) | [44.2](/filings/0001193125-25-280234.md) | [59.4](/filings/0001193125-26-064005.md) | [49.3](/filings/0001193125-26-204047.md) | [75.9](/filings/0001193125-26-330631.md) | [49.7](/filings/0001193125-25-280234.md) | [45.7](/filings/0001193125-26-330631.md) | [56.4](/filings/0001193125-26-204047.md) | [37.5](/filings/0001193125-26-330631.md) |
| Current assets | $m | [232](/filings/0000950170-23-059415.md) | [213](/filings/0000950170-25-022273.md) | [324](/filings/0000950170-24-053582.md) | [295](/filings/0000950170-24-095467.md) | [279](/filings/0000950170-24-125471.md) | [262](/filings/0001193125-26-064005.md) | [211](/filings/0000950170-25-063564.md) | [291](/filings/0000950170-25-107359.md) | [296](/filings/0001193125-25-280234.md) | [288](/filings/0001193125-26-330631.md) | [290](/filings/0001193125-26-204047.md) | [274](/filings/0001193125-26-330631.md) |
| Total assets | $m | [274](/filings/0000950170-23-059415.md) | [252](/filings/0000950170-25-022273.md) | [351](/filings/0000950170-24-053582.md) | [329](/filings/0000950170-24-095467.md) | [302](/filings/0000950170-24-125471.md) | [274](/filings/0001193125-26-064005.md) | [243](/filings/0000950170-25-063564.md) | [347](/filings/0000950170-25-107359.md) | [431](/filings/0001193125-25-280234.md) | [409](/filings/0001193125-26-330631.md) | [437](/filings/0001193125-26-204047.md) | [405](/filings/0001193125-26-330631.md) |
| Current liabilities | $m | [18.9](/filings/0000950170-23-059415.md) | [20.5](/filings/0000950170-25-022273.md) | [15.2](/filings/0000950170-24-053582.md) | [19.5](/filings/0000950170-24-095467.md) | [21.2](/filings/0000950170-24-125471.md) | [24.8](/filings/0001193125-26-064005.md) | [17.6](/filings/0000950170-25-063564.md) | [18.1](/filings/0000950170-25-107359.md) | [20.2](/filings/0001193125-25-280234.md) | [20.4](/filings/0001193125-26-330631.md) | [17.8](/filings/0001193125-26-204047.md) | [20.8](/filings/0001193125-26-330631.md) |
| Total liabilities | $m | [26.9](/filings/0000950170-23-059415.md) | [27.9](/filings/0000950170-25-022273.md) | [22.1](/filings/0000950170-24-053582.md) | [26.5](/filings/0000950170-24-095467.md) | [28.1](/filings/0000950170-24-125471.md) | [31.0](/filings/0001193125-26-064005.md) | [23.1](/filings/0000950170-25-063564.md) | [22.9](/filings/0000950170-25-107359.md) | [24.3](/filings/0001193125-25-280234.md) | [24.5](/filings/0001193125-26-330631.md) | [21.2](/filings/0001193125-26-204047.md) | [23.4](/filings/0001193125-26-330631.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [247](/filings/0000950170-24-125471.md) | [224](/filings/0001193125-26-064005.md) | [329](/filings/0001193125-25-280234.md) | [302](/filings/0001193125-25-280234.md) | [274](/filings/0001193125-25-280234.md) | [243](/filings/0001193125-26-330631.md) | [220](/filings/0001193125-26-330631.md) | [324](/filings/0001193125-26-330631.md) | [407](/filings/0001193125-25-280234.md) | [384](/filings/0001193125-26-330631.md) | [416](/filings/0001193125-26-330631.md) | [381](/filings/0001193125-26-330631.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(19.6) d](/filings/0000950170-24-125471.md) | [(24.3) d](/filings/0000950170-25-022273.md) | [(30.2)](/filings/0000950170-25-063564.md) | [(25.6) d](/filings/0000950170-25-107359.md) | [(28.8) d](/filings/0001193125-25-280234.md) | [(28.1) d](/filings/0001193125-26-064005.md) | [(32.5)](/filings/0001193125-26-204047.md) | [(30.8) d](/filings/0001193125-26-330631.md) | [(25.1) d](/filings/0001193125-25-280234.md) | [(22.5) d](/filings/0001193125-26-064005.md) | [(32.4)](/filings/0001193125-26-204047.md) | [(31.6) d](/filings/0001193125-26-330631.md) |
| Capital expenditure | $m | [0.1 d](/filings/0000950170-24-125471.md) | [0.1 d](/filings/0000950170-25-022273.md) | [0.2](/filings/0000950170-25-063564.md) | [0.3 d](/filings/0000950170-25-107359.md) | [0.4 d](/filings/0001193125-25-280234.md) | [0.2 d](/filings/0001193125-26-064005.md) | [0.4](/filings/0001193125-26-204047.md) | [0.1 d](/filings/0001193125-26-330631.md) | [0.0 d](/filings/0001193125-25-280234.md) | [0.2 d](/filings/0001193125-26-064005.md) | [0.0](/filings/0001193125-26-204047.md) | [0.4 d](/filings/0001193125-26-330631.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [39.6](/filings/0000950170-23-059415.md) | [45.1](/filings/0000950170-24-053582.md) | [45.7](/filings/0000950170-24-095467.md) | [57.4](/filings/0000950170-24-125471.md) | [67.3](/filings/0000950170-25-063564.md) | [70.3](/filings/0000950170-25-107359.md) | [70.5](/filings/0001193125-25-280234.md) | [71.0](/filings/0001193125-26-204047.md) | [78.1](/filings/0001193125-26-330631.md) | [99.0](/filings/0001193125-25-280234.md) | [105](/filings/0001193125-26-204047.md) | [108](/filings/0001193125-26-330631.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 103,652,656 at 2026-07-27, from the cover of the [10-Q filed 2026-08-03](/filings/0001193125-26-330631.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.